TPN10466 ameliorates Concanavalin A‐induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway
European Journal of Immunology · 2023
DOI: 10.1002/eji.202250100 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2023. Verfasst von Guangyu Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of…. Hauptthemen laut MEDLINE: Artemisinins, Hepatitis, Autoimmune. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Autoimmune hepatitis (AIH) eventually progresses to liver fibrosis, cirrhosis, and even hepatocellular carcinoma, causing irreversible damage to the liver. Concanavalin A‐induced hepatitis in mice is a well‐established model with pathophysiology similar to that of immune‐mediated liver injury in human viral and autoimmune hepatitis, and it has been widely used to explore the pathogenesis and clinical treatment of human immune hepatitis. Artemisinin has been shown to exhibit anti‐inflammatory effects through unclear mechanisms. In this study, we aimed to assess the effect of the artemisinin derivative TPN10466 on AIH. In vitro studies showed that TPN10466 dose dependently inhibited the percentage of IFN‐γ‐producing T cells. Further studies showed that TPN10466 attenuated the disease severity of AIH by downregulating the ability of lymphocytes to secrete IFN‐γ and by reducing lymphocyte number in the liver. In addition, we found that TPN10466 treatment reduced T‐cell responses by inhibiting JNK, ERK, and p38 pathways. In conclusion, our work suggests that TPN10466 provides protection against the autoimmune disease AIH by suppressing the inflammatory response of T cells, suggesting that TPN10466 may be a promising potential agent for the treatment of AIH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, China.
- Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- CAS Key Laboratory for Receptor Research, Shanghai Institute of Materia, Medica, Chinese Academy of Sciences, Shanghai, China.
Zitieren
APA
Liu, G., Zhang, Y., Han, S., Zhuang, W., Lv, J., Han, M., Xie, L., Jiang, X., Wang, C., Saimaier, K., Shen, J., & Du, C. (2023). TPN10466 ameliorates Concanavalin A‐induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway. European Journal of Immunology. https://doi.org/10.1002/eji.202250100
Vancouver
Liu G, Zhang Y, Han S, Zhuang W, Lv J, Han M, et al. TPN10466 ameliorates Concanavalin A‐induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway. European Journal of Immunology. 2023. doi:10.1002/eji.202250100
BibTeX
@article{Liu2023,
author = {Liu, Guangyu and Zhang, Yan and Han, Sansheng and Zhuang, Wei and Lv, Jie and Han, Mengyao and Xie, Ling and Jiang, Xiangrui and Wang, Chun and Saimaier, Kaidireya and Shen, Jingshan and Du, Changsheng},
title = {TPN10466 ameliorates Concanavalin A‐induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway},
journal = {European Journal of Immunology},
year = {2023},
doi = {10.1002/eji.202250100}
}
EUVIMED